BioCardia Earnings Call: Key Takeaways
BioCardia is pivoting toward Japanese regulatory approval for Cardiamp and US de novo approval for Helix, while managing a tight $2.2 million cash runway into 2027.
- Call
- Nov 12, 2026, 4:30 PM ET
ALFA USA Filings
Every alert, straight from SEC EDGAR
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All BioCardia, Inc. filings on SEC EDGAR ↗
Filing type
Alerts
Time
3 alerts with these filters
BioCardia is pivoting toward Japanese regulatory approval for Cardiamp and US de novo approval for Helix, while managing a tight $2.2 million cash runway into 2027.
BioCardia reported financial results for the third quarter ended September 30, 2026, and provided updates on its regulatory progress in Japan and the U.S. The company successfully completed pre-submission interactions with Japan's PMDA for its CardiAMP cell therapy and expects to file for FDA De Novo approval of its Helix delivery system in Q1 2027.
“We believe that our CardiAMP autologous cell therapy is on track to be the first approved minimally invasive biologic therapy for the treatment of heart failure in a first world country based on the recent interactions with Japan’s Pharmaceutical and Medical Devices Agency.”
Peter Altman, PhD, Chief Executive Officer of BioCardia
“In addition, in the coming months, we aim to be able to submit our Helix transendocardial delivery platform for FDA approval, which would be the first delivery system of its type approved in the United States. This promises to be an exciting year ahead.”
Peter Altman, PhD, Chief Executive Officer of BioCardia
BioCardia, Inc. reported a net loss of $5.7 million for the nine months ended September 30, 2026, compared to a $6.2 million loss in the prior year period. The company ended the quarter with $2.2 million in cash and cash equivalents, supported by $5.3 million in proceeds from common stock sales during the year.